2018 American Transplant Congress
Tregs Expression Predicts Prognosis in Patients with Hepatocellular Carcinoma
New therapeutic strategies are needed to improve the survival of patients with hepatocellular carcinoma (HCC), the third in overall global cancer-related mortality. T regulatory cells…2018 American Transplant Congress
Utility of Combining Stereotactic Body Radiation Therapy (SBRT) to Transarterial Chemoembolization as Destination Therapy for Hepatocellular Cancer (HCC) within Milan Criteria
University of Iowa Hospitals and Clinics, Iowa City.
Limited data are available on the effect of SBRT in patients with HCC within Milan. We aimed to compare TACE followed by SBRT with TACE…2018 American Transplant Congress
Radiation Exposure to the Transplant Surgeon: A Case Study of Recent Yttrium-90 Treatment in an Explanted Liver
BACKGROUND: Yttrium-90 (Y-90) radioembolization for the treatment of hepatocellular carcinoma can present safety challenges to the surgeon when transplanting a recently treated Y-90 patient. To…2018 American Transplant Congress
T Cell Lineage Imbalance and Regulatory Immune Populations in HCC Patients Undergoing Downstaging While Waitlisted for Liver Transplantation
Purpose:In this study, we monitored peripheral lymphocyte lineage and regulatory immune populations in HCC patients undergoing DEB-TACE as a bridge to liver transplantation.Methods: Liver transplant…2018 American Transplant Congress
Impact of Mammalian Target of Rapamycin Inhibitors on Hepatocellular Carcinoma Recurrence after Liver Transplant
Despite limited benefit to patients within Milan criteria on explant, mTORi are routinely utilized for prevention of hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT).…2018 American Transplant Congress
Liver Transplantation for Patients with Hepatocellular Carcinoma Presenting beyond Milan Criteria: Analysis of 789 Patients from the US Multicenter HCC Transplant Consortium
Objective: OPTN has recently approved MELD prioritization for HCC patients beyond Milan Criteria (MC) who are downstaged (DS) with locoregional therapy (LRT) prior to liver…2018 American Transplant Congress
Liver Transplantation for Hepatocellular Carcinoma Outperform Other Populations in the New Hepatitis C Era
Background: Long term results of HCC liver transplants (LTx) in the recent era of direct-acting antivirals (DAA) against hepatitis C (HCV) are not available. We…2018 American Transplant Congress
Improving Prognostication amongst Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma: An International, 16-Center Study to Validate and Recalibrate HALTHCC
Objective: Prognosticating outcomes in liver transplant (LT) for hepatocellular carcinoma (HCC) continues to challenge the field. Whereas adoption of the binary Milan Criteria (MC) generalized…2018 American Transplant Congress
Predictive Value of mRECIST in HCC Response to the Neoadjuvant Locoregional Therapies and Prognosis Affected by the Peak AFP Level before Liver Transplantation
PURPOSE: The modified response evaluation criteria in solid tumors (mRECIST) has been used to assess the response of hepatocellular carcinoma (HCC) to locoregional therapy (LRT)…2018 American Transplant Congress
HLA-DR4 Matching and Hepatocellular Carcinoma Recurrence after Liver Transplantation
PURPOSE: The phenomenon of graft versus host disease after orthotopic liver transplantation (OLT) is estimated at approximately 1-2%, suggesting that under some circumstances, the graft…
American Transplant Congress abstracts